Four magnetic resonance imaging surveillance-detected breast cancer cases in cancer-free BRCA1/2 mutation carriers.

BRCA Breast cancer Hereditary breast and ovarian cancer syndrome MRI surveillance

Journal

Surgical case reports
ISSN: 2198-7793
Titre abrégé: Surg Case Rep
Pays: Germany
ID NLM: 101662125

Informations de publication

Date de publication:
21 Oct 2021
Historique:
received: 27 08 2021
accepted: 15 10 2021
entrez: 21 10 2021
pubmed: 22 10 2021
medline: 22 10 2021
Statut: epublish

Résumé

Hereditary breast and ovarian cancer (HBOC) syndrome is a susceptibility syndrome for cancers, such as breast and ovarian cancer, and BRCA1/2 are its causative genes. Annual breast-enhanced magnetic resonance imaging (MRI) is recommended for BRCA1/2 mutation carriers aged over 25 years as a secondary prevention of breast cancer. However, breast MRI surveillance is rarely performed in Japan, and only four cases of breast cancer diagnosis triggered by MRI surveillance have been reported. At our hospital, MRI triggered the diagnosis of breast cancer in four cancer-free BRCA1/2 mutation carriers. In one of our four cases, although MRI showed only a 3-mm focus, we could diagnose breast cancer by shortening the surveillance interval considering the patient's high-risk for developing breast cancer. Image-guided biopsy, including MRI-guided biopsy, depending on the size of the lesion, and shorter surveillance intervals are useful when there are potentially malignant findings on breast MRI surveillance for cancer-free patients with HBOC.

Sections du résumé

BACKGROUND BACKGROUND
Hereditary breast and ovarian cancer (HBOC) syndrome is a susceptibility syndrome for cancers, such as breast and ovarian cancer, and BRCA1/2 are its causative genes. Annual breast-enhanced magnetic resonance imaging (MRI) is recommended for BRCA1/2 mutation carriers aged over 25 years as a secondary prevention of breast cancer. However, breast MRI surveillance is rarely performed in Japan, and only four cases of breast cancer diagnosis triggered by MRI surveillance have been reported.
CASE PRESENTATION METHODS
At our hospital, MRI triggered the diagnosis of breast cancer in four cancer-free BRCA1/2 mutation carriers. In one of our four cases, although MRI showed only a 3-mm focus, we could diagnose breast cancer by shortening the surveillance interval considering the patient's high-risk for developing breast cancer.
CONCLUSIONS CONCLUSIONS
Image-guided biopsy, including MRI-guided biopsy, depending on the size of the lesion, and shorter surveillance intervals are useful when there are potentially malignant findings on breast MRI surveillance for cancer-free patients with HBOC.

Identifiants

pubmed: 34674065
doi: 10.1186/s40792-021-01313-5
pii: 10.1186/s40792-021-01313-5
pmc: PMC8531180
doi:

Types de publication

Journal Article

Langues

eng

Pagination

228

Informations de copyright

© 2021. The Author(s).

Références

Radiology. 2008 Jan;246(1):58-70
pubmed: 18096529
Cancer. 1999 May 15;85(10):2200-5
pubmed: 10326698
J Clin Oncol. 2007 Apr 10;25(11):1329-33
pubmed: 17416853
Magn Reson Med Sci. 2017 Jul 10;16(3):265-269
pubmed: 28090007
Breast Cancer. 2019 Sep;26(5):552-561
pubmed: 30820924
Breast Cancer. 2019 Nov;26(6):846-851
pubmed: 30980249
Gland Surg. 2021 Jan;10(1):262-272
pubmed: 33633982
J Clin Oncol. 2010 Mar 20;28(9):1450-7
pubmed: 20177029
Arch Gynecol Obstet. 2014 Mar;289(3):663-70
pubmed: 24045978
N Engl J Med. 2021 Jun 24;384(25):2394-2405
pubmed: 34081848

Auteurs

Megumi Takaoka (M)

Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan. megumi.tkk0731@gmail.com.

Shozo Ohsumi (S)

Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.

Yuichiro Miyoshi (Y)

Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.

Mina Takahashi (M)

Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.

Seiki Takashima (S)

Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.

Kenjiro Aogi (K)

Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.

Teruhiko Shimizu (T)

Department of Radiology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.

Norihiro Teramoto (N)

Department of Pathology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.

Yasuko Yamamoto (Y)

Department of Familial Tumor, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.

Miki Okamura (M)

Department of Familial Tumor, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.

Classifications MeSH